Status: current, Defined. Date: 31-Jan 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 2471188018 | Epidermal growth factor receptor inhibitor | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 3520637019 | Epidermal growth factor receptor antagonist | en | Synonym | Active | Case insensitive | SNOMED CT core |
| 4589761011 | Substance with epidermal growth factor receptor inhibitor mechanism of action (substance) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| 4589762016 | EGFR (epidermal growth factor receptor) inhibitor | en | Synonym | Active | Case sensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Epidermal growth factor receptor antagonist | Is a | Enzyme inhibitor | false | Inferred relationship | Some | ||
| Epidermal growth factor receptor antagonist | Is a | Protein kinase inhibitor | true | Inferred relationship | Some | ||
| Epidermal growth factor receptor antagonist | Is a | Antineoplastic agent | true | Inferred relationship | Some | ||
| Epidermal growth factor receptor antagonist | Is a | Protein-tyrosine kinase inhibitor | false | Inferred relationship | Some | ||
| Epidermal growth factor receptor antagonist | Has disposition | Epidermal growth factor receptor antagonist | true | Inferred relationship | Some | ||
| Epidermal growth factor receptor antagonist | Is a | Substance categorized by disposition | false | Inferred relationship | Some | ||
| Epidermal growth factor receptor antagonist | Is a | Receptor antagonist | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Osimertinib mesilate | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Gefitinib | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Erlotinib hydrochloride | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Erlotinib | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Lapatinib | Is a | False | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Lapatinib ditosylate | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Vandetanib | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Lapatinib ditosylate monohydrate | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Human epidermal growth factor receptor 2 inhibitor | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Amivantamab | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Disorder of skin caused by epidermal growth factor receptor inhibitor | Causative agent | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | 1 |
| Cetuximab | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Epidermal growth factor receptor antagonist antineoplastic agent | Has active ingredient | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | 1 |
| Protein-tyrosine kinase inhibitor | Is a | False | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Panitumumab | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Osimertinib | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Necitumumab | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some | |
| Nimotuzumab | Is a | True | Epidermal growth factor receptor antagonist | Inferred relationship | Some |
Reference Sets
Substance foundation reference set
FHIR